By Adriano Marchese
Canopy Growth shares fell as a decline in Canadian adult-use cannabis weighed heavily on the company's revenue in the second fiscal quarter, days after an industry-wide collapse in cannabis stocks.
Shares traded 7.8% lower at 5.81 Canadian dollars ($4.19).
The Smiths Falls, Ontario-based cannabis company reported a 9% decline in total revenue to C$63 million, missing consensus expectations of C$64.2 million, according to FactSet.
Canopy saw a significant decline in Canadian adult-use cannabis, where revenue fell 24% to C$18.4 million. This offset the 16% gain from Canadian medical cannabis which reached C$18.7 million, and international markets cannabis which rose 12% to C$10.1 million.
The decline follows recent industry-wide pullback in cannabis stocks, in which Canopy wasn't spared, after initiatives to legalize recreational marijuana in Florida, North Dakota and South Dakota failed to receive enough votes.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 08, 2024 10:50 ET (15:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。